Anti-emetic efficacy of oral granisetron in the total control of late-onset emesis induced by cyclophosphamide-containing chemotherapy
Tóm tắt
Effectiveness of 5-HT3 receptor antagonists in preventing cyclophosphamide-induced emesis suggests that it is mediated by serotonin release. Since urinary 5-hydroxyindoleacetic acid (5-HIAA) is not significantly increased, the mechanism of emesis induction remains poorly understood, and the usefulness of these drugs in late-onset emesis prevention remains controversial. In this randomised, double-blind, and placebo-controlled trial, 139 chemotherapy-naïve breast cancer patients received intravenous chemotherapy combinations containing cyclophosphamide at doses ≥500 mg/m2. Total antiemetic control was the primary efficacy parameter. On day 0 all patients received intravenous granisetron (3 mg) prior to chemotherapy. On day 1 patients were randomly assigned either to oral granisetron (1 mg bid) or to placebo, for a 2-day course. Patients remained hospitalised during the study period. Rescue therapy (up to 2 doses of i.v. granisetron 3 mg) was promptly administered should there be a second episode of vomiting. Twenty-four hour urine samples were collected on days −1 to +2, for analysis of 5-HIAA excretion. Relative to the control group, significantly more patients in the oral granisetron group experienced total control of emesis on day 1 (67% versus 49%; p=0.04), on day 2 (76% versus 52%; p<0.01), and on days 1–2 (60% versus 42%; p=0.04). Excretion of 5-HIAA was significantly increased on day 0, day 1 and day 2 compared to levels on day −1 (p<0.01 for all paired comparisons). The type of chemotherapy administered and the patient's history of vomiting were the variables influencing the total control of emesis. Oral granisetron provided high rates of effective and safe control of late-onset emesis induced by cyclophosphamide-based chemotherapy. Urinary excretion of 5-HIAA was significantly increased during the entire emesis period.
Tài liệu tham khảo
Frytak S, Moertel CG. Management of nausea and vomiting in the cancer patient. JAMA 1981;245:393–6.
Osoba D, Zee B, Warr D, et al. Quality of life studies in chemotherapy-induced emesis. Oncology 1996;53 Suppl 1:S92–5.
Lazlo J, Lucas VS Jr. Emesis as a critical problem in chemotherapy. N Engl J Med 1981;305:948–9.
Mertens WC, Higby DJ, Brown D, et al. Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol 2003;21:1373–8.
Roscoe JA, Morrow GR, Hickok JT, et al. Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manage 2000;20:113–21.
Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 1999;17:2971–94.
Barnes NM, Ge J, Jones WG, et al. Cisplatin induced emesis: preliminary results indicative of changes in plasma levels of 5-hydroxytryptamine. Br J Cancer 1990;62:862–4.
Cubbedu LX, Hoffmann IS, Fuenmayor NT, et al. Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs. Br J Cancer 1992;66:198–203.
Cubbedu LX, Hoffmann IS, Fuenmayor NT, et al. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990;322:810–6.
Du Bois A, Vach W, Wechsel U, et al. 5-hydroxyindoleacetic acid (5-HIAA) and cortisol excretion as predictors of chemotherapy-induced emesis. Br J Cancer 1996;74: 1137–40.
Wilder-Smith OHG, Borgeat A, Chappuis P, et al. Urinary serotonin metabolite excretion durign cisplatin chemotherapy. Cancer 1993;72:2239–41.
Cubeddu LX, Hoffmann IS. Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: effects of antiemetics. J Clin Pharmacol 1993;33:691–7.
Du Bois A, Siebert C, Vach W, et al. Cisplatin-induced alterations of serotonin metabolism in patients with or without emesis following chemotherapy. Oncol Rep 1995;2:839–42.
Du Bois A, Kriesinger-Schroeder H, Meerpohl H-G. The role of serotonin as a mediator of emesis induced by different stimuli. Support Care Cancer 1995;3:285–90.
Verweij J, de Wit R, de Mulder PHM. Optimal control of acute cisplatin-induced emesis. Oncology 1996;53 Suppl 1:S56–64.
Chua DT, Sham JS, Kwong DL, et al. Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study. Am J Clin Oncol 2000;23:185–91.
Hesketh P. Management of cisplatin-induced delayed emesis. Oncology 1996;53 Suppl 1:S73–7.
Tsukada H, Hirose T, Yokoyama A, et al. Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis. Eur J Cancer 2001;37:2398–404.
Italian Group for Antiemetic Research. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Support Care Cancer 2000;8:229–32.
Stewart A. Optimal control of cyclophosphamide-induced emesis. Oncology 1996;53 Suppl 1:S32–8.
Martin M. The severity and pattern of emesis following different cytotoxic agents. Oncology 1996;53 Suppl 1:S26–31.
Beck TM. The pattern of emesis following high-dose cyclophosphamide and the anti-emetic efficacy of ondansetron. Anti-Cancer Drugs 1995;6:237–42.
Kaizer L, Warr D, Hoskins P, et al. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994;12:1050–7.
The Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995;332:1–5.
Lofters WS, Pater L, Zee B, et al. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 1997;15:2966–73.
Cubeddu LX, Hoffmann IS, Fuenmayor NT, et al. Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs. Br J Cancer 1992;66:198–203.
Cubeddu LX, O'Connor DT, Hoffmann I, et al. Plasma chromogranin A marks emesis and sertonin release associated with dacarbazine and nitrogen mustard but not with cyclophosphamide-based chemotherapies. Br J Cancer 1995;72:1033–8.
Du Bois A, Vach W, Holy R, et al. 5-hydroxyindoleacetic acid excretion following combination chemotherapy with cyclophosphamide, epirubicine and 5-fluorouracil plus ondansetron compared to ondasetron alone. Support Care Cancer 1996;4:384–9.
Antiemetic Subcomitte of the Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemotherapy-and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol 1998;9:811–9.
Olver IN. Antiemetic study methodology: recommendations for future studies. Oncology 1996;53 Suppl 1:S96–101.
Alfieri AB, Cubeddu LX. Effects of inhibition of serotonin synthesis on 5-hydroxyindoleacetic acid excretion, in healthy subjects. J Clin Pharmacol 1994;34:153–7.
Sharma AM, Schorr U, Thiede H-M, et al. Effect of dietary salt restriction on urinary serotonin and 5-hydroxyindoleacetic acid excretion in man. J Hypertens 1993:11:1381–6.
Sparrow D, O'Connor GT, Young JB, et al. Relationship of urinary serotonin excretion to cigarette smoking and respiratory symptoms. Chest 1992;101:976–80.
Fujita K, Maruta K, Ito S, et al. Urinary 4-hydroxy-3-methoxymandelic (vanillylmandelic) acid, 4-hydroxy-3-methoxymandelic (homovanillic) acid, and 5-hydroxyindoeacetic acid determined by liquid chromatography with electrochemical detection. Clin Chem 1983;29:876–8.
Bartels H, Bohmer M. Micro-determination of creatinine. Clin Chim Acta 1971;32:81–5.
Goodin S, Cunningham R. 5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile. Oncologist 2002;7:424–36.
Sanger GJ. The pharmacology of anti-emetic agents. In: Andrews PLR, Sanger GJ, editors. Emesis in anti-cancer therapy: mechanisms and treatment. London: Chapman & Hall Medical, 1993, p. 179–210.
Martin M, Díaz-Rubio E. Emesis during past pregnancy: a new prognostic factor in chemotherapy induced emesis. Ann Oncol 1990;1:152–3.
Morrow GR. The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy. Cancer 1985;55:2766–70.
Campos D, Pereira JR, Reinhardt RR, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001;19:1759–67.
Redd WH, Montgomery GH, DuHamel KN. Behavioral intervention for cancer treatment side effects. J Natl Cancer Inst 2001;93:810–23.
Shen J, Wenger N, Glaspy J, et al. Electroacupuncture for control of myeloablative chemotherapy-induced emesis: A randomized controlled trial. JAMA 2000;284:2755–61.
Molassiotis A. A pilot study of the use of progressive muscle relaxation training in the management of postchemotherapy nausea and vomiting. Eur J Cancer Care 2000;9:230–4.
Dupuis LL, Lau R, Greenberg ML. Delayed nausea and vomiting in children receiving antineoplastics. Med Pediatr Oncol 2001;37:115–21.
Santini D, Vincenzi B, Fossati C, et al. Prevention of delayed emesis induced by moderately emetogenic chemotherapy in patients with acute emesis: a pilot study with ACTH-Depot plus tropisetron. Med Oncol 2001;18:131–5.
Gralla RJ. New agents, new treatment, and antiemetic therapy. Semin Oncol 2002;29(1 Suppl 4):119–24.